Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
60 Alzheimer's Disease Trials near Phoenix, AZ
Power is an online platform that helps thousands of Alzheimer's Disease patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerBuntanetap for Alzheimer's Disease
Phoenix, Arizona
The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are:
* Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13?
* Does buntanetap/Posiphen improve function as measured by ADCS-iADL?
* What medical issues do participants have, if any, when taking buntanetap/Posiphen?
Researchers will compare buntanetap/Posiphen to a placebo (a look-alike substance that contains no drug) to see if buntanetap/Posiphen works to treat early Alzheimer's disease.
Participants will:
* Take buntanetap/Posiphen or a placebo every day for 18 months
* Visit the clinic periodically for checkups, tests, and questionnaires (screening visits, enrollment, month 1, month 3, month 6, month 9, month 12, month 15, month 18), including a volumetric MRI at month 6 and month 18
* Complete pre- and post-clinic visit phone calls
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:55 - 85
Key Eligibility Criteria
Disqualifiers:Schizophrenia, Bipolar, Major Depression, Others
Must Be Taking:Cholinesterase Inhibitors, Memantine
760 Participants Needed
ALZ-801 for Early Alzheimer's Disease
Phoenix, Arizona
This study is being conducted to evaluate the long-term safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is an open-label trial of treatment with ALZ-801.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:50 - 85
Key Eligibility Criteria
Disqualifiers:Moderate-severe ARIA, Others
Must Not Be Taking:Amyloid Antibodies
163 Participants Needed
Donanemab for Alzheimer's Disease
Phoenix, Arizona
This trial is testing donanemab, a medication aimed at helping people with Alzheimer's Disease by removing harmful protein clumps from their brains. Donanemab has shown promise in reducing these harmful proteins in Alzheimer's disease.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:65 - 80
Key Eligibility Criteria
Disqualifiers:Mild Cognitive Impairment, Dementia, Cancer, Others
Must Not Be Taking:Cognitive Enhancers
2996 Participants Needed
Screening for Alzheimer's Disease Studies
Phoenix, Arizona
This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50 - 90
Key Eligibility Criteria
Disqualifiers:Neurological Conditions, CNS Trauma, Others
13000 Participants Needed
KarXT for Psychosis in Alzheimer's Disease
Phoenix, Arizona
The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:55 - 90
Key Eligibility Criteria
Disqualifiers:Schizophrenia, Bipolar, Major Depression, Others
406 Participants Needed
KarXT for Alzheimer's-Related Psychosis
Phoenix, Arizona
This trial is testing KarXT, a medication for adults aged 55-90 with Alzheimer's Disease and severe psychosis. The goal is to see if KarXT can reduce symptoms like hallucinations and delusions by balancing brain chemicals.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:55 - 90
Key Eligibility Criteria
Disqualifiers:Bipolar, Schizophrenia, Major Depression, Others
400 Participants Needed
[18F]PI-2620 PET Imaging for Alzheimer's Disease
Phoenix, Arizona
This trial tests a brain scan that uses a special substance to detect harmful proteins in people with Alzheimer's disease.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50+
Key Eligibility Criteria
Disqualifiers:Aggressive Treatment, Brain Lesions, Others
Must Not Be Taking:Amyloid, Tau Therapies
200 Participants Needed
AR1001 for Alzheimer's Disease
Phoenix, Arizona
This trial tests AR1001, a medicine for early Alzheimer's Disease. It focuses on people in the early stages of Alzheimer's, aiming to improve their condition through multiple mechanisms.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:55 - 90
Key Eligibility Criteria
Disqualifiers:Pregnancy, Delirium, Schizophrenia, Cancer, Others
Must Be Taking:Cholinesterase Inhibitors, Memantine
1150 Participants Needed
KarXT for Alzheimer's-Associated Psychosis
Phoenix, Arizona
This trial is testing KarXT, a medication, to see if it can prevent psychotic symptoms from returning in people with Alzheimer's Disease. It works by balancing brain chemicals that cause hallucinations and delusions. KarXT has shown positive results in reducing symptoms of schizophrenia.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:55 - 90
Key Eligibility Criteria
Disqualifiers:Bipolar, Schizophrenia, Severe Renal Impairment, Others
Must Be Taking:Cholinesterase Inhibitors, Memantine
380 Participants Needed
Semaglutide for Early Alzheimer's Disease
Phoenix, Arizona
This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.
Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance.
The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10 of the clinic visits participants will have blood samples taken.
Participants must have a study partner, who is willing to take part in the study.
Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study period.
A cerebrospinal fluid (CSF) sub-study will be performed as a part of the study. The sub-study will be performed on a selection of sites based on their experience with CSF sampling and willingness to participate in this sub-study. The endpoints related to this sub-study are exploratory only.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:55 - 85
Key Eligibility Criteria
Disqualifiers:Parkinson's, Schizophrenia, Bipolar, Others
Must Be Taking:Alzheimer's Treatments
1840 Participants Needed
Donanemab for Early Alzheimer's Disease
Phoenix, Arizona
This trial is testing donanemab, a drug for early Alzheimer's disease. It targets people with early symptoms and specific brain changes. The drug helps remove harmful proteins from the brain, potentially slowing down or improving symptoms.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:60 - 85
Key Eligibility Criteria
Disqualifiers:MRI/PET Contraindication, Others
Must Not Be Taking:Immunoglobulin G Therapy
1736 Participants Needed
ONO-2020 for Alzheimer's Disease
Phoenix, Arizona
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD). This study aims to determine whether administering ONO-2020, an epigenetic regulator, may improve cognitive functions like memory and cognition in individuals with Alzheimer's disease dementia.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:55 - 85
Key Eligibility Criteria
Disqualifiers:Stroke, Schizophrenia, HIV, Others
Must Be Taking:Acetylcholinesterase Inhibitors, Memantine
240 Participants Needed
BMS-986368 for Alzheimer's Disease
Phoenix, Arizona
This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:55 - 90
Key Eligibility Criteria
Disqualifiers:Bipolar, Schizophrenia, Schizoaffective, Others
120 Participants Needed
E2814 + Lecanemab for Alzheimer's Disease
Phoenix, Arizona
The primary objective of the study is to determine the dose response of E2814, when concurrently administered with lecanemab, on the change from baseline at 18 months in cerebrospinal fluid (CSF) microtubule-binding region (MTBR)-tau-243 in participants with early Alzheimer's disease (AD).
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:50 - 80
Key Eligibility Criteria
Disqualifiers:Neurological Conditions, Stroke, Seizures, Others
Must Be Taking:Acetylcholinesterase Inhibitors
105 Participants Needed
JNJ-64042056 for Alzheimer's Disease
Phoenix, Arizona
The purpose of this study is to assess the effect of JNJ-64042056 on cognitive decline, as measured by Preclinical Alzheimer's disease Cognitive Composite 5 (PACC-5) compared with placebo.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:55 - 75
Key Eligibility Criteria
Disqualifiers:Alzheimer's Dementia, Mild Cognitive Impairment, Others
498 Participants Needed
Mevidalen for Alzheimer's Disease
Phoenix, Arizona
The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease (AD) dementia. This is done by looking at participants: thinking and memory (cognition), everyday activities and sleep, AD symptoms, physical activity, irritability or anxiety. The study is expected to last approximately 26 weeks and may include up to 14 visits.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:50 - 80
Key Eligibility Criteria
Disqualifiers:Childbearing Potential, CNS Disease, Others
Must Not Be Taking:CYP3A4 Inhibitors, Inducers
300 Participants Needed
Benfotiamine for Alzheimer's Disease
Phoenix, Arizona
The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer's disease.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:50 - 89
Key Eligibility Criteria
Disqualifiers:Neurological Disorders, Diabetes, Cancer, Others
Must Be Taking:Acetylcholinesterase Inhibitors, Memantine
406 Participants Needed
CT1812 for Early Alzheimer's Disease
Phoenix, Arizona
This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:50 - 85
Key Eligibility Criteria
Disqualifiers:Other Dementias, Neurodegenerative Conditions, Hepatitis, Others
540 Participants Needed
ACU193 for Early Alzheimer's Disease
Phoenix, Arizona
The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:50 - 90
Key Eligibility Criteria
Disqualifiers:Neurological Disease, Malignant Disease, Depression, Others
Must Be Taking:Cholinesterase Inhibitors, Memantine
542 Participants Needed
ABBV-916 for Early Alzheimer's Disease
Phoenix, Arizona
This trial is testing a new drug called ABBV-916 to see if it can help people aged 50-90 who are in the early stages of Alzheimer's disease. Participants will receive the drug regularly over several months. The study aims to find out if the drug is safe and effective by monitoring changes in symptoms and side effects.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:50 - 90
Key Eligibility Criteria
Disqualifiers:Vasogenic Edema, Microhemorrhages, Others
Must Not Be Taking:Anticoagulants
106 Participants Needed
Why Other Patients Applied
"I watched my mother die from Parkinson’s. At the time of her death, she weighed 85 pounds and could not move any muscles voluntarily except her eyelids. I would like to participate in a trial to help find a better treatment for PD than what is currently available. It is a devastating illness. It breaks my heart that other families will have to go through this."
WU
Healthy Volunteer PatientAge: 76
"I have a very strong family history of Alzheimer’s, with my maternal grandmother, mother, uncle, and sister having the disease. My APOE status is 2/4. My memory is going, although 6 months ago I tested decently on some cognitive tests. I'd like to help myself by getting ahead of my condition and help others in a similar situation by participating in medical research."
EK
Mild Cognitive Impairment PatientAge: 72
"I have been on standard Alzheimer's medication for a few years but know this treatment only works to delay my cognitive deterioration, not improve it. I've been doing research, which brought me here, to consider some of the latest research drugs. While I know that there's no guarantee that a clinical trial improves my condition, I'd like to give one a try and help further the research for all."
VL
Alzheimer's PatientAge: 71
"I'm so used to losing things, forgetting things, making up to acronyms to remember things only to remember the acromym but not what the letters stand for... I enter a new room to look for an item, only to forget what I was looking for. I've discussed the existing treatments with my neurologist and she's on board with my joining a clinical trial."
AH
Dementia PatientAge: 64
"I watched my mother suffer through years of Alzheimer's Disease and I want to help advance the science for treating AD. I don't want anyone else to have go through what our family went through."
OF
Alzheimer's Disease PatientAge: 65
Alzheimer's Disease Vaccine for Alzheimer's Disease
Phoenix, Arizona
Phase 1 clinical trial of AV-1959 amyloid-β vaccine for Alzheimer's disease (AD).
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:60 - 85
Key Eligibility Criteria
Disqualifiers:Insulin-dependent Diabetes, Autoimmune Diseases, Others
Must Be Taking:Acetylcholine Esterase Inhibitors, Memantine
48 Participants Needed
Adaptive Aerobic Exercise for Alzheimer's Disease
Phoenix, Arizona
The goal of this clinical trial is to test 6 months of aerobic exercise in older adults who are 65 years or older and have mild cognitive impairment (MCI) or probable/possible mild Alzheimer's Disease. The main questions it aims to answer are:
* test the effects of aerobic exercise on aerobic fitness, white matter hyperintensity (WMH) volume, and patient-centered outcomes;
* identify the best exercise to improve aerobic fitness and reduce non-responses over 6 months; and
* examines the mechanisms of aerobic exercise's action on memory in older adults with early AD.
Participants will receive 6 months of supervised exercise, undergo cognitive data collection and exercise testing 5 times over a year span, have an MRI brain scan 3 times over a one-year span, and have monthly follow-up discussions on health and wellness.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:65+
Key Eligibility Criteria
Disqualifiers:Unstable Depression, Unstable Anxiety, Others
Must Not Be Taking:Antidepressants
216 Participants Needed
Sensory Stimulation for Alzheimer's Disease
Phoenix, Arizona
This trial is testing a device that uses light and sound to help patients with mild to moderate Alzheimer's disease. The goal is to see if this sensory stimulation can slow down the progression of the disease by improving brain function. This therapy has shown potential for application in the treatment of Alzheimer's disease.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:50 - 90
Key Eligibility Criteria
Disqualifiers:Seizure Disorder, Schizophrenia, Heart Disease, Others
Must Be Taking:Acetylcholinesterase Inhibitors
600 Participants Needed
Sensory Stimulation for Alzheimer's Disease
Phoenix, Arizona
This is an open-label extension for a multicenter, randomized, double-blind, sham-controlled, adaptive design pivotal study.
Participants who complete the Hope Study (CA-0011) will be eligible to consent for screening to enroll in the OLE Hope Study (CA-0015). All participants will be treated with an Active Sensory Stimulation System (GS120) for 60 minutes daily for up to 12 months. There will be no Sham treatment group or randomization involved in this study.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:50 - 92
Key Eligibility Criteria
Disqualifiers:Insufficient Adherence, Continuous Care, Others
Must Not Be Taking:Immunomodulators, Memantine, Nootropics
402 Participants Needed
Long-Term Safety of Simufilam for Alzheimer's Disease
Phoenix, Arizona
The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RETHINK-ALZ or REFOCUS-ALZ Phase 3 clinical trials.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Age:51 - 89
Key Eligibility Criteria
Disqualifiers:Not Listed
1081 Participants Needed
AMDX-2011P for Alzheimer's Disease
Phoenix, Arizona
The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with Alzheimer's Disease (AD).
No Placebo Group
Trial Details
Trial Status:Recruiting
Key Eligibility Criteria
Disqualifiers:Not Listed
25 Participants Needed
AL002 for Alzheimer's Disease
Phoenix, Arizona
This trial tests AL002, a drug for early Alzheimer's disease, in people who were part of an earlier study. It aims to check if AL002 is safe and effective over time.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Age:50 - 85
Key Eligibility Criteria
Disqualifiers:Not Listed
188 Participants Needed
MK-1167 for Alzheimer's Disease
Phoenix, Arizona
Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Alzheimer's disease dementia (AD dementia), such as memory and mental activity. AD dementia is the most common type of dementia. AChEI therapy is the standard treatment for AD dementia.
The goals of this study are to learn:
* If at least one dose level (amount) of MK-1167 works to improve a person's memory and thinking compared to a placebo
* About the safety of MK-1167 and if people tolerate it
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:55 - 90
Key Eligibility Criteria
Disqualifiers:Stroke, CNS Disease, Seizures, Others
Must Be Taking:Acetylcholinesterase Inhibitors
350 Participants Needed
Psychoeducational Skills Training for Mild Cognitive Impairment
Phoenix, Arizona
EPICLA+ (Early-Stage Partners in Care Living Alone Plus) is a research project designed to assist people with early-stage memory loss who live alone in the community by providing early-stage related education and skill-training sessions, held via Zoom, designed to reduce stress, enhance well-being, manage challenges, and plan for the future. Researchers will gather feedback from individuals about their experience to continue to improve programs for early-stage memory loss.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:60+
Key Eligibility Criteria
Disqualifiers:Hearing, Visual Impairment, Others
70 Participants Needed
Siponimod for Alzheimer's Disease
Phoenix, Arizona
Collaboration with multiple sclerosis (MS) specialty colleagues led us to formulate the central hypothesis that Siponimod could lower the rate of brain atrophy in Alzheimer's disease (AD) subjects. To test our central hypothesis, we will carry out an 18-month Phase II, double-blind, randomized, twoarmed, placebo controlled, proof-of-concept clinical study in early AD subjects (i.e. mild AD) who will be receiving an escalating dose of Siponimod or placebo in the ratio 2:1 for 12 months, followed by a 6-month washout period. The primary outcome measures are safety and tolerability of Siponimod in mild AD subjects. The secondary outcome measures are the rates of brain atrophy derived from volumetric MRI (vMRI) as a proxy for neurodegeneration conducted at baseline, 6, 12, and 18 months. The tertiary outcome measures are the changes in cognition and the levels of AD-associated (e.g., Aβ and tau) and inflammatory biomarkers in CSF after Siponimod exposure. In an exploratory effort, we will also measure plasma inflammatory markers during the entire duration of the study to investigate whether one or more of these markers can be used as dynamic surrogate markers of treatment response. Using our unique experience with the repurposing of immunomodulatory drugs for AD (and NCT #04032626), in the present project we are using elements of clinical trial design that we believe were successful and made some adjustments to fit the pharmacologic and toxic properties of Siponimod.
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 2
Age:50 - 85
Key Eligibility Criteria
Disqualifiers:Infections, Neurological Illness, Hypertension, Others
Must Not Be Taking:Cancer Drugs, Amiodarone, Sulfa Drugs, Others
105 Participants Needed
Know someone looking for new options?
Spread the word